Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients58

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients24

Views

Views
April 20252
May 20250
June 20250
July 202518
August 20250
September 20253
October 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil8
United States7
Spain2
Ecuador1
Ethiopia1
United Kingdom1
Honduras1
Kenya1
Senegal1
Turkey1
 

Top cities views

Views
Dallas2
Anápolis1
Arujá1
Awasa1
Brasília1
Carangola1
Casimiro de Abreu1
Council Bluffs1
Dakar1
Detroit1